Developer docs
API playgroundTry for free, no card

Search company profiles

F-star Therapeutics, Inc.

Full company profile

uuid02lzlm7

Namestring
F-star Therapeutics, Inc.
Legal namestring
F-star Therapeutics, Inc.
Websiteurl
sbpgroup.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

F-star Therapeutics, Inc. was a clinical-stage biopharmaceutical company that developed bispecific antibody-based immunotherapies for the treatment of cancer. The company's core technology was its proprietary mAb² bispecific antibody platform, which uses Fcab binding domains to generate tetravalent bispecific antibodies in native human antibody formats; the platform was described as offering manufacturing simplicity, safety, and biological efficacy advantages. F-star's lead clinical asset was FS222, a CD137/PD-L1 bispecific antibody, for which positive Phase I data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting after the company's integration into Sino Biopharm.

The company was previously publicly listed on NASDAQ under the ticker FSTX. In 2023, Sino Biopharm (中国生物制药有限公司, HKEX: 1177) completed the acquisition of F-star Therapeutics, integrating its bispecific antibody platform and pipeline into the group's overseas innovation subsidiary, invoX Pharma Limited (UK). Post-acquisition, F-star ceased to operate as an independent publicly traded entity. Within the Sino Biopharm group, the F-star platform contributes to the group's antibody-based oncology pipeline development alongside complementary modalities including monoclonal antibodies, antibody-drug conjugates (ADCs), siRNA, and PROTAC. As a wholly-owned subsidiary rather than a standalone commercial enterprise, F-star generates no standalone revenue and its value is realized through the parent group's broader licensing, partnership, and commercialization activities.

Short descriptiontext

F-star Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody-based cancer immunotherapies, anchored by its proprietary mAb² platform using Fcab binding domains. It was acquired by Sino Biopharm in 2023 and now operates within invoX Pharma.

Operating statusenum
Acquired
Ownership categoryenum
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody platforms, cancer immunotherapy, antibody therapeutics, oncology biologics, bispecific antibody discovery
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bispecific Antibody Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1创新药销售
TypeOne Time License
Description

聚焦肿瘤、肝病/心血管代谢、呼吸/自免、外科/镇痛四大核心治疗领域,通过自主研发产品及战略合作引进产品进行商业化销售。2025年全年创新产品收入达152.2亿元,年复合增长率超24%,同比增速达到26.2%

sbpgroup.com
2对外授权与合作
TypeLicensing Royalties
Description

将自主研发产品海外权益授权给跨国药企,获得首付款、里程碑付款及特许权使用费。如与阿斯利康就TQC3721达成最高19亿美元授权,与赛诺菲就罗伐昔替尼达成独家授权

sbpgroup.com
3产品引进与合作商业化
TypeSubscription Recurring
Description

通过与GSK、勃林格殷格翰、盐野义等跨国药企的战略合作,引进创新产品在中国市场商业化,如全再乐、欧乐欣、纳地美定等

sbpgroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
Pricing details1 tier
1处方药及创新药产品组合
ModelOtherBilling cadenceOther
Notes

产品通过国家医保目录谈判、医疗机构采购等渠道销售,覆盖超过9000家医院及基层医疗机构

sbpgroup.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1mAb²® Bispecific Antibody Technology Platform
Description

F-star's proprietary bispecific antibody technology platform used to generate tetravalent bispecific antibodies with native human antibody formats. This platform underpinned F-star's clinical pipeline including FS222.

sbpgroup.com
Core offering1 text field

F-star Therapeutics developed proprietary mAb² bispecific antibody technology platforms for cancer immunotherapy. Its lead clinical asset was FS222 (CD137/PD-L1 bispecific antibody), with Phase I clinical data presented at the 2024 ASCO Annual Meeting. In 2023, F-star was acquired by Sino Biopharm (中国生物制药, 1177.HK) and its technology platform was integrated into the group's UK-based overseas innovation subsidiary invoX Pharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2025年全年创新产品收入达152.2亿元,年复合增长率超24%
+3 more records
Product overview1 text field

Based on the source data provided, F-star Therapeutics, Inc. appears as an acquired biotech company rather than as a primary data source. The content indicates that Sino Biopharm (中国生物制药, 1177.HK) acquired F-star in 2023 to obtain its bispecific antibody platform technology. The company's FS222 (CD137/PD-L1 bispecific antibody) was mentioned as the first research result from the F-star platform presented at an international conference following the acquisition. No other specific F-star product details, integrations, APIs, or technical specifications were found in the provided source material.

Product and service2 records
1mAb² Bispecific Antibody Technology Platform
CategoryBispecific Antibody Platform Technology
Description

F-star's proprietary bispecific antibody technology platform used to generate tetravalent bispecific antibodies with native human antibody formats. The platform uses Fcab binding domains and offers simple manufacturing processes, safety, and notable bioequivalence profiles. It underpinned F-star's clinical pipeline including FS222 and was the central asset acquired by Sino Biopharm in 2023.

2FS222 (CD137/PD-L1 bispecific antibody)
CategoryClinical-Stage Oncology Biologic
Description

F-star's lead clinical-stage bispecific antibody candidate targeting CD137 and PD-L1 for cancer immunotherapy. FS222 showed positive Phase I clinical data presented at the 2024 ASCO Annual Meeting under Sino Biopharm's ownership following the 2023 acquisition.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Tempo Scan Pacific
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2026-07-27
Description

在印度尼西亚成立合资公司PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI),中国生物制药持股51%,Tempo Scan持股49%。结合双方在创新药物研发与本地化商业化方面的优势

sbpgroup.com
Strategic tier核心TypeStrategic or Co-development PartnerAnnounced on2026-07-08
Description

2026年5月,中国生物制药与GSK就Bepirovirsen乙肝治疗药物达成独家战略合作。2026年7月,进一步扩大合作,将全再乐(氟替美维吸入粉雾剂)和欧乐欣(乌美溴铵维兰特罗吸入粉雾剂)在中国内地的商业化运营权授予正大天晴,覆盖超过9000家医院及基层医疗机构

3阿斯利康
Strategic tier核心TypeStrategic or Co-development PartnerAnnounced on2026-07-08
Description

就自主研发的PDE3/4抑制剂TQC3721订立独家授权协议,授予阿斯利康中国以外地区开发、生产及商业化的独家许可。获得2亿美元首付款及最高19亿美元里程碑付款

sbpgroup.com
4南京大学
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2026-07-02
Description

正大天晴与南京大学签署战略合作协议,从科技创新、成果转化、平台共建、人才培养、产业合作五大维度全面落地,深化全方位校企合作

sbpgroup.com
5盐野义
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

纳地美定(Naldemedine)(欣璞落)获NMPA批准上市,该药为全球首个获批的口服选择性外周μ-阿片受体拮抗剂,由盐野义研发,正大天晴负责中国市场商业化

sbpgroup.com
6赛诺菲
Strategic tier核心TypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

就罗伐昔替尼达成独家全球许可协议,创下移植领域单笔交易额新记录,标志着公司从药物立项到生产质控的全链条研发能力获得国际认可

sbpgroup.com
7赫吉亚生物医药
Strategic tier核心TypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

以12亿元人民币全资收购杭州赫吉亚生物医药,获得siRNA技术平台,在减重代谢、心脑血管及神经系统等大慢病领域布局创新管线

sbpgroup.com
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2024-12-09
Description

正大天晴与香港中文大学医学院签署合作框架协议,推动包括临床试验、人才联合培养等在内的多领域合作,加速两地创新生物医药研究成果转化

9华润医药商业
Strategic tier重要TypeChannel Partner/ Reseller/ DistributorAnnounced on2024-06-12
Description

正大天晴与华润医药商业在天津签署战略合作协议,在医药研发、生产、销售、流通等领域展开深度合作

sbpgroup.com
10益方生物
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

2023年8月正大天晴与益方生物签订许可与合作协议,获得KRAS G12C靶向药物D-1553产品在中国大陆地区开发、注册、生产和商业化的独家许可权

sbpgroup.com
11勃林格殷格翰
Strategic tier重要TypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

签署战略合作协议,将依托各自优势和资源,共同研发并在中国内地商业化勃林格殷格翰的肿瘤药物管线

sbpgroup.com
12礼新医药
Strategic tier核心TypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

2025年7月全资收购礼新医药,获得全球领先的抗体发现与ADC技术平台,以及LM-302(CLDN18.2 ADC)、LM-108(CCR8单抗)等多款全球潜在FIC/BIC产品

sbpgroup.com
Strategic tier一般TypeStrategic or Co-development PartnerAnnounced on2023-06-02
Description

invoX完成对下一代mRNA疫苗公司pHion Therapeutics的第二笔投资,支持其专有的RALA平台发展,推进HPV相关癌症治疗性疫苗PTX_V1进入临床试验

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AstraZeneca is a multinational biopharmaceutical company actively developing bispecific antibodies (e.g., Tagrisso combination strategies) and is a current partner/licensee of Sino Biopharm. It is relevant as both a broad incumbent in the bispecific space and as a counterparty providing F-star's parent validation.

TypeDirect peer
Description

Innovent Biologics is a Chinese biopharmaceutical company developing and commercializing innovative biologics including bispecific antibodies. It is directly comparable to F-star as a China-based biologics innovator with overlapping therapeutic focus areas and similar global ambitions.

TypeBroad incumbent
Description

Regeneron is a major biopharmaceutical company with significant bispecific antibody capabilities through its VelociBi platform (linvoseltamab, odronextamab, etc.). It is a broader incumbent comparable to F-star in terms of bispecific antibody development but operates at substantially greater scale.

TypeDirect peer
Description

MacroGenics is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-based therapeutics using proprietary DART and TRIDENT platforms. It is directly comparable to F-star as a bispecific-platform-focused clinical-stage oncology developer.

TypeDirect peer
Description

Zymeworks develops multispecific antibody therapeutics using its Azymetric and other proprietary platforms, with oncology pipeline assets in clinical development. It is directly comparable to F-star as a multispecific/bispecific platform company targeting oncology indications.

TypeDirect peer
Description

Genmab is a leading bispecific antibody platform company (DuoBody, HexaBody, DuoHexaBody) developing and commercializing multispecific therapeutics across oncology and immunology. It is the most directly comparable peer to F-star because it shares the bispecific platform business model and targets similar therapeutic areas.

TypeDirect peer
Description

Merus develops bispecific antibody therapeutics (Biclonics and Triclonics platforms) with multiple clinical-stage oncology candidates including petosemamab. It is directly comparable to F-star given its similar bispecific platform orientation and clinical-stage oncology focus.

TypeDirect peer
Description

Akeso is a Chinese clinical-stage biopharmaceutical company specializing in bispecific and multispecific antibody development, including approved assets such as cadonilimab (PD-1/CTLA-4 bispecific). It is a direct peer to F-star given its bispecific-focused business model and comparable geographic base.

TypeDirect peer
Description

Harpoon Therapeutics developed T cell-engaging bispecific antibodies using its TriTAC and ProTriTAC platforms and was acquired by Merck in 2024. It is a directly comparable bispecific platform peer, particularly relevant given its acquisition by a major pharma validating the bispecific platform thesis.

TypeEmerging player
Description

Inhibrx developed multispecific biologics including a tetravalent PD-L1/4-1BB therapeutic that was licensed by Sanofi in 2024. Its tetravalent PD-L1/CD137 bispecific is conceptually similar to F-star's FS222 (also PD-L1/CD137), making it a strong emerging-player comparison.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

F-star Therapeutics, Inc.

Bispecific Antibody Therapeuticssbpgroup.com

F-star Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody-based cancer immunotherapies, anchored by its proprietary mAb² platform using Fcab binding domains. It was acquired by Sino Biopharm in 2023 and now operates within invoX Pharma.

What F-star Therapeutics, Inc. does

F-star Therapeutics, Inc. was a clinical-stage biopharmaceutical company that developed bispecific antibody-based immunotherapies for the treatment of cancer. The company's core technology was its proprietary mAb² bispecific antibody platform, which uses Fcab binding domains to generate tetravalent bispecific antibodies in native human antibody formats; the platform was described as offering manufacturing simplicity, safety, and biological efficacy advantages. F-star's lead clinical asset was FS222, a CD137/PD-L1 bispecific antibody, for which positive Phase I data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting after the company's integration into Sino Biopharm.

The company was previously publicly listed on NASDAQ under the ticker FSTX. In 2023, Sino Biopharm (中国生物制药有限公司, HKEX: 1177) completed the acquisition of F-star Therapeutics, integrating its bispecific antibody platform and pipeline into the group's overseas innovation subsidiary, invoX Pharma Limited (UK). Post-acquisition, F-star ceased to operate as an independent publicly traded entity. Within the Sino Biopharm group, the F-star platform contributes to the group's antibody-based oncology pipeline development alongside complementary modalities including monoclonal antibodies, antibody-drug conjugates (ADCs), siRNA, and PROTAC. As a wholly-owned subsidiary rather than a standalone commercial enterprise, F-star generates no standalone revenue and its value is realized through the parent group's broader licensing, partnership, and commercialization activities.

F-star Therapeutics, Inc. firmographics

Firmographics
Name
F-star Therapeutics, Inc.
Legal name
F-star Therapeutics, Inc.
Website
https://sbpgroup.com
Company type
Private
Operating status
Acquired
Short description
F-star Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody-based cancer immunotherapies, anchored by its proprietary mAb² platform using Fcab binding domains. It was acquired by Sino Biopharm in 2023 and now operates within invoX Pharma.
Ownership category
akta.pro rank

F-star Therapeutics, Inc. industry classification

Industry
Product category
Bispecific Antibody Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Bispecific antibody platforms
  • Cancer immunotherapy
  • Antibody therapeutics
  • Oncology biologics
  • Bispecific antibody discovery

Where F-star Therapeutics, Inc. is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices7 records

Markets served

F-star Therapeutics, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. 创新药销售: 聚焦肿瘤、肝病/心血管代谢、呼吸/自免、外科/镇痛四大核心治疗领域,通过自主研发产品及战略合作引进产品进行商业化销售。2025年全年创新产品收入达152.2亿元,年复合增长率超24%,同比增速达到26.2%
  2. 对外授权与合作: 将自主研发产品海外权益授权给跨国药企,获得首付款、里程碑付款及特许权使用费。如与阿斯利康就TQC3721达成最高19亿美元授权,与赛诺菲就罗伐昔替尼达成独家授权
  3. 产品引进与合作商业化: 通过与GSK、勃林格殷格翰、盐野义等跨国药企的战略合作,引进创新产品在中国市场商业化,如全再乐、欧乐欣、纳地美定等

Pricing tiers

ModelBillingPrice
OtherOther处方药及创新药产品组合

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

F-star Therapeutics, Inc. product offering

Product offering

Core offering

F-star Therapeutics developed proprietary mAb² bispecific antibody technology platforms for cancer immunotherapy. Its lead clinical asset was FS222 (CD137/PD-L1 bispecific antibody), with Phase I clinical data presented at the 2024 ASCO Annual Meeting. In 2023, F-star was acquired by Sino Biopharm (中国生物制药, 1177.HK) and its technology platform was integrated into the group's UK-based overseas innovation subsidiary invoX Pharma.

Product overview

Based on the source data provided, F-star Therapeutics, Inc. appears as an acquired biotech company rather than as a primary data source. The content indicates that Sino Biopharm (中国生物制药, 1177.HK) acquired F-star in 2023 to obtain its bispecific antibody platform technology. The company's FS222 (CD137/PD-L1 bispecific antibody) was mentioned as the first research result from the F-star platform presented at an international conference following the acquisition. No other specific F-star product details, integrations, APIs, or technical specifications were found in the provided source material.

Differentiator

Problem solved

Functional benefit

Brands

  • mAb²® Bispecific Antibody Technology Platform: F-star's proprietary bispecific antibody technology platform used to generate tetravalent bispecific antibodies with native human antibody formats. This platform underpinned F-star's clinical pipeline including FS222.

Products and services

  • mAb² Bispecific Antibody Technology Platform F-star's proprietary bispecific antibody technology platform used to generate tetravalent bispecific antibodies with native human antibody formats. The platform uses Fcab binding domains and offers simple manufacturing processes, safety, and notable bioequivalence profiles. It underpinned F-star's clinical pipeline including FS222 and was the central asset acquired by Sino Biopharm in 2023.
  • FS222 (CD137/PD-L1 bispecific antibody) F-star's lead clinical-stage bispecific antibody candidate targeting CD137 and PD-L1 for cancer immunotherapy. FS222 showed positive Phase I clinical data presented at the 2024 ASCO Annual Meeting under Sino Biopharm's ownership following the 2023 acquisition.

Quantifiable outcome

  • 2025年全年创新产品收入达152.2亿元,年复合增长率超24%
  • +3 more outcomes

Companies that use F-star Therapeutics, Inc.

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles1 record

F-star Therapeutics, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

F-star Therapeutics, Inc. partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered 重要, 核心 and 一般.

  • Tempo Scan Pacific重要Strategic or Co-development Partner · 27 July 2026在印度尼西亚成立合资公司PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI),中国生物制药持股51%,Tempo Scan持股49%。结合双方在创新药物研发与本地化商业化方面的优势
  • 葛兰素史克(GSK)核心Strategic or Co-development Partner · 8 July 20262026年5月,中国生物制药与GSK就Bepirovirsen乙肝治疗药物达成独家战略合作。2026年7月,进一步扩大合作,将全再乐(氟替美维吸入粉雾剂)和欧乐欣(乌美溴铵维兰特罗吸入粉雾剂)在中国内地的商业化运营权授予正大天晴,覆盖超过9000家医院及基层医疗机构
  • 阿斯利康核心Strategic or Co-development Partner · 8 July 2026就自主研发的PDE3/4抑制剂TQC3721订立独家授权协议,授予阿斯利康中国以外地区开发、生产及商业化的独家许可。获得2亿美元首付款及最高19亿美元里程碑付款
  • 南京大学重要Strategic or Co-development Partner · 2 July 2026正大天晴与南京大学签署战略合作协议,从科技创新、成果转化、平台共建、人才培养、产业合作五大维度全面落地,深化全方位校企合作
  • 盐野义重要Strategic or Co-development Partner · 29 May 2026纳地美定(Naldemedine)(欣璞落)获NMPA批准上市,该药为全球首个获批的口服选择性外周μ-阿片受体拮抗剂,由盐野义研发,正大天晴负责中国市场商业化
  • 赛诺菲核心Strategic or Co-development Partner · 4 March 2026就罗伐昔替尼达成独家全球许可协议,创下移植领域单笔交易额新记录,标志着公司从药物立项到生产质控的全链条研发能力获得国际认可
  • 赫吉亚生物医药核心Strategic or Co-development Partner · 13 January 2026以12亿元人民币全资收购杭州赫吉亚生物医药,获得siRNA技术平台,在减重代谢、心脑血管及神经系统等大慢病领域布局创新管线
  • 香港中文大学医学院重要Strategic or Co-development Partner · 9 December 2024正大天晴与香港中文大学医学院签署合作框架协议,推动包括临床试验、人才联合培养等在内的多领域合作,加速两地创新生物医药研究成果转化
  • 华润医药商业重要Channel Partner/ Reseller/ Distributor · 12 June 2024正大天晴与华润医药商业在天津签署战略合作协议,在医药研发、生产、销售、流通等领域展开深度合作
  • 益方生物重要Strategic or Co-development Partner · 1 June 20242023年8月正大天晴与益方生物签订许可与合作协议,获得KRAS G12C靶向药物D-1553产品在中国大陆地区开发、注册、生产和商业化的独家许可权
  • 勃林格殷格翰重要Strategic or Co-development Partner · 1 January 2024签署战略合作协议,将依托各自优势和资源,共同研发并在中国内地商业化勃林格殷格翰的肿瘤药物管线
  • 礼新医药核心Strategic or Co-development Partner · 1 January 20242025年7月全资收购礼新医药,获得全球领先的抗体发现与ADC技术平台,以及LM-302(CLDN18.2 ADC)、LM-108(CCR8单抗)等多款全球潜在FIC/BIC产品
  • pHion Therapeutics一般Strategic or Co-development Partner · 2 June 2023invoX完成对下一代mRNA疫苗公司pHion Therapeutics的第二笔投资,支持其专有的RALA平台发展,推进HPV相关癌症治疗性疫苗PTX_V1进入临床试验

Scale indicators11 records

Recent moves4 records

Expansion highlights4 records

F-star Therapeutics, Inc. competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: AstraZeneca is a multinational biopharmaceutical company actively developing bispecific antibodies (e.g., Tagrisso combination strategies) and is a current partner/licensee of Sino Biopharm. It is relevant as both a broad incumbent in the bispecific space and as a counterparty providing F-star's parent validation.
  • Regeneron Pharmaceuticals: Regeneron is a major biopharmaceutical company with significant bispecific antibody capabilities through its VelociBi platform (linvoseltamab, odronextamab, etc.). It is a broader incumbent comparable to F-star in terms of bispecific antibody development but operates at substantially greater scale.

Direct peers

  • Innovent Biologics: Innovent Biologics is a Chinese biopharmaceutical company developing and commercializing innovative biologics including bispecific antibodies. It is directly comparable to F-star as a China-based biologics innovator with overlapping therapeutic focus areas and similar global ambitions.
  • MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-based therapeutics using proprietary DART and TRIDENT platforms. It is directly comparable to F-star as a bispecific-platform-focused clinical-stage oncology developer.
  • Zymeworks: Zymeworks develops multispecific antibody therapeutics using its Azymetric and other proprietary platforms, with oncology pipeline assets in clinical development. It is directly comparable to F-star as a multispecific/bispecific platform company targeting oncology indications.
  • Genmab: Genmab is a leading bispecific antibody platform company (DuoBody, HexaBody, DuoHexaBody) developing and commercializing multispecific therapeutics across oncology and immunology. It is the most directly comparable peer to F-star because it shares the bispecific platform business model and targets similar therapeutic areas.
  • Merus N.V. Merus develops bispecific antibody therapeutics (Biclonics and Triclonics platforms) with multiple clinical-stage oncology candidates including petosemamab. It is directly comparable to F-star given its similar bispecific platform orientation and clinical-stage oncology focus.
  • Akeso Inc. Akeso is a Chinese clinical-stage biopharmaceutical company specializing in bispecific and multispecific antibody development, including approved assets such as cadonilimab (PD-1/CTLA-4 bispecific). It is a direct peer to F-star given its bispecific-focused business model and comparable geographic base.
  • Harpoon Therapeutics (acquired by Merck): Harpoon Therapeutics developed T cell-engaging bispecific antibodies using its TriTAC and ProTriTAC platforms and was acquired by Merck in 2024. It is a directly comparable bispecific platform peer, particularly relevant given its acquisition by a major pharma validating the bispecific platform thesis.

Emerging players

  • Inhibrx (acquired by Sanofi): Inhibrx developed multispecific biologics including a tetravalent PD-L1/4-1BB therapeutic that was licensed by Sanofi in 2024. Its tetravalent PD-L1/CD137 bispecific is conceptually similar to F-star's FS222 (also PD-L1/CD137), making it a strong emerging-player comparison.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

F-star Therapeutics, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

F-star Therapeutics, Inc. leadership team

Management profile

Number of profiles

F-star Therapeutics, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

F-star Therapeutics, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about F-star Therapeutics, Inc.

What does F-star Therapeutics, Inc. do?

F-star Therapeutics developed proprietary mAb² bispecific antibody technology platforms for cancer immunotherapy. Its lead clinical asset was FS222 (CD137/PD-L1 bispecific antibody), with Phase I clinical data presented at the 2024 ASCO Annual Meeting. In 2023, F-star was acquired by Sino Biopharm (中国生物制药, 1177.HK) and its technology platform was integrated into the group's UK-based overseas innovation subsidiary invoX Pharma.

Is F-star Therapeutics, Inc. a public or private company?

F-star Therapeutics, Inc. is a private company. It is classified as corporate owned and is currently acquired.

When was F-star Therapeutics, Inc. founded?

F-star Therapeutics, Inc. was founded in -1.

Where is F-star Therapeutics, Inc. based?

F-star Therapeutics, Inc. is headquartered in Cambridge, United Kingdom, in the Europe region.

How does F-star Therapeutics, Inc. make money?

Three revenue lines are on record. 创新药销售 is the primary driver. The others are 对外授权与合作 and 产品引进与合作商业化.

Who are F-star Therapeutics, Inc.'s main competitors?

Broad incumbents on record are AstraZeneca and Regeneron Pharmaceuticals. Direct peers are Innovent Biologics, MacroGenics, Zymeworks, Genmab, Merus N.V., Akeso Inc. and Harpoon Therapeutics (acquired by Merck). Inhibrx (acquired by Sanofi) is listed as an emerging player.

Does F-star Therapeutics, Inc. have an API?

No public API is recorded for F-star Therapeutics, Inc..

What industry is F-star Therapeutics, Inc. in?

F-star Therapeutics, Inc.'s product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireThinking about buying stock in Troika Media, Snap, F-Star Therapeutics, Ambrx Biopharma, or SoundHound AI?InvestorsObserver issued critical PriceWatch Alerts for stocks including Troika Media (TRKA), Snap (SNAP), F-Star Therapeutics (FSTX), Ambrx Biopharma (AMAM), and SoundHound AI (SOUN). The alerts are generated using a proprietary scoring system that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. InvestorsObserver provides this technology to Wall Street firms and self-directed investors.PR NewswireThinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?InvestorsObserver issued PriceWatch Alerts for five biotechnology and medical device stocks: Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, and TG Therapeutics. The alerts are based on a proprietary scoring system evaluating short-term technical, long-term technical, and fundamental factors to determine investment suitability.GlobeNewswireF-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate HighlightsF-star Therapeutics reported Q2 2022 net loss of $19.0 million and cash of $53.0 million. The company agreed to be acquired by invoX Pharma for $7.12 per share, expected to close in H2 2022. It also advanced clinical programs, including FS118 clearing a futility hurdle.BioSpaceinvoX Pharma Commences Tender Offer for F-star Therapeutics, Inc.invoX Pharma, a Sino Biopharm subsidiary, commenced a cash tender offer for all F-star Therapeutics shares at $7.12 per share on July 7, 2022. The offer expires August 3, 2022, with a merger to follow if stockholders tender over 50% of shares.BenzingaNasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet - (APLT)U.S. stocks saw an increase, with the Nasdaq Composite gaining over 100 points. Applied Therapeutics, Inc. shares dropped 24% following the announcement of a $30 million public offering of common stock and warrants. Meanwhile, F-star Therapeutics, Inc. experienced a significant rise after it was announced Sino Biopharmaceutical's invoX Pharma would acquire the company for $7.12 per share, valuing it at approximately $161 million.BenzingaThe Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, XenoThis article is a daily roundup of multiple unrelated developments in the biotech sector, including Sino Biopharma's acquisition of F-Star Therapeutics and regulatory approvals for VBI Vaccines' brain cancer candidate and Amryt Pharma's skin disease treatment. It also covers clinical data from Xenon Pharmaceuticals, FDA feedback for Rockwell Medical, and Merck's vaccine recommendation by the CDC. The report includes financial updates on public offerings by several companies.GlobeNewswireinvoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical ProgramsinvoX Pharma, a Sino Biopharm subsidiary, agreed to acquire F-star Therapeutics for $7.12 per share, valuing the company at approximately $161 million. The all-cash deal, expected to close in the second half of 2022, adds F-star's tetravalent bispecific antibody platform to invoX's oncology pipeline.GlobeNewswireF-star Therapeutics to Present at Upcoming Investor ConferencesF-star Therapeutics will participate in two virtual investor conferences next week, including a fireside chat with CEO Eliot Forster and a panel on multispecific therapies with CSO Neil Brewis. The company will also host 1:1 management meetings on July 13 and 14.BioSpaceF-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common StockF-star Therapeutics announced the pricing of a $65 million public offering of common stock, selling 9,285,715 shares at $7.00 per share with an expected closing date around May 11, 2021. The company intends to use the net proceeds for working capital, general corporate purposes, and ongoing clinical trials and research activities. SVB Leerink is acting as the sole bookrunning manager for the underwritten offering.GlobeNewswireF-star Therapeutics, Inc. Announces Proposed Public Offering of Common StockF-star Therapeutics commenced an underwritten public offering of its common stock, with underwriters granted a 30-day option to buy up to 15% more shares. Proceeds will fund working capital, clinical trials, and R&D. The offering is subject to market conditions and a preliminary prospectus supplement will be filed.